On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver

2016 ◽  
Vol 95 (10) ◽  
pp. 1571-1582 ◽  
Author(s):  
Leonidas Benetatos ◽  
Georgios Vartholomatos
Blood ◽  
2019 ◽  
Vol 134 (24) ◽  
pp. 2195-2208 ◽  
Author(s):  
Daniel Sasca ◽  
Haiyang Yun ◽  
George Giotopoulos ◽  
Jakub Szybinski ◽  
Theo Evan ◽  
...  

Cohesin mutations are common in myeloid malignancy. Sasca et al elucidate the potential role of cohesin loss in myelodysplastic syndrome and acute myeloid leukemia (MDS/AML). They demonstrate that cohesin binding is critical for erythroid-specific gene expression and that reduction in cohesin impairs terminal erythroid maturation and promotes myeloid malignancy.


2007 ◽  
Vol 3 (4) ◽  
pp. 475-480 ◽  
Author(s):  
Jerry C Cheng ◽  
Samuel Esparza ◽  
Salemiz Sandoval ◽  
Deepa Shankar ◽  
Cecilia Fu ◽  
...  

2014 ◽  
Vol 90 (1) ◽  
pp. 1-16 ◽  
Author(s):  
Heidrun Karlic ◽  
Harald Herrmann ◽  
Franz Varga ◽  
Roman Thaler ◽  
Rene Reitermaier ◽  
...  

2008 ◽  
Vol 49 (12) ◽  
pp. 2246-2255 ◽  
Author(s):  
Shahram Mori ◽  
Jorge Cortes ◽  
Hagop Kantarjian ◽  
Weiguo Zhang ◽  
Michael Andreef ◽  
...  

2018 ◽  
Vol 25 (8) ◽  
pp. 2035-2037 ◽  
Author(s):  
Craig W Freyer ◽  
James K Mangan

We describe a case of dose-related periorbital edema in a patient with FLT3-mutated acute myeloid leukemia taking sorafenib and voriconazole that resolved following sorafenib dose reduction. We hypothesize that the mechanism of this adverse event may be related to the inhibition of platelet-derived growth factor receptor (PDGFR) by sorafenib. Clinicians should be aware of this possible dose-related adverse event and the potential role of sorafenib dose reduction when on concurrent voriconazole.


2011 ◽  
Vol 29 (18) ◽  
pp. 2507-2513 ◽  
Author(s):  
Yiming Chen ◽  
Jorge Cortes ◽  
Zeev Estrov ◽  
Stefan Faderl ◽  
Wei Qiao ◽  
...  

Purpose To determine the prognostic impact of persistent cytogenetic abnormalities at complete remission (CR) on relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) and to examine the potential role of allogeneic stem-cell transplantation (SCT) in this setting. Patients and Methods Data from 254 adult patients with AML (excluding acute promyelocytic leukemia) who achieved CR after induction chemotherapy on various first-line protocols were examined. Results Median follow-up for surviving patients was 43 months. Patients with cytogenetic abnormalities at CR (n = 71) had significantly shorter RFS (P = .001) and OS (P < .001) compared with patients with normal cytogenetics at CR (n = 183); 3-year RFS was 15% and 45%, and 3-year OS was 15% and 56%, respectively. Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT in first CR (CR1; n = 15) had better RFS and OS compared to those without SCT (n = 56; P = .04 and .06, respectively). In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predictor for RFS (P < .001) and OS (P = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differences in OS (P = .25) was observed between those who did or did not receive SCT with a trend favoring SCT for RFS (P = .08). Conclusion Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS. SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 2587-2587
Author(s):  
Kehan Ren ◽  
Yang Mei ◽  
Yijie Liu ◽  
Xu Han ◽  
Ermin Li ◽  
...  

Abstract The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterize by cytopenia(s), dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, and increased risk of development of acute myeloid leukemia (AML). Growing evidence revealed the significance of pyroptotic cell death in the inflammatory bone marrow in MDS. However, the detailed mechanisms of pyroptosis in the pathogenesis and progression of MDS remain unknown. Gasdermin D is a pore-forming protein that is cleaved upon inflammasome assembly by inflammatory caspases at the linker between the N-terminus pore-forming domain and the C-terminus autoinhibitory domain. The activation of gasdermin D results in increased cell permeability, cell pyroptosis, and the release of cytokines including Interleukin 1 (IL-1) family. Binding of these cytokines to the IL-1 receptor triggers the activation and release of other pro-inflammatory cytokines, including IL-6 and tumor necrosis factor (TNF). Our group recently established a Diap1 (encoding mDia1) and miR-146a double knockout (DKO) mouse model phenocopying MDS. These two genes are involved in the innate immune signaling and inflammation. DKO mice develop aging-related anemia and thrombocytopenia with over-secretion of pro-inflammatory cytokines. Many DKO mice progress to acute myeloid leukemia (AML) with monocytic differentiation and bone marrow fibrosis at 12 months of age. We found that gasdermin D is upregulated and activated (cleaved) in the bone marrow and spleens of the DKO mice. To study the role of gasdermin D in MDS, we crossed DKO mice with gasdermin D knock out mice to generate gasdermin D, mDia1, miR-146a triple knock out (TKO) mice. Gasdermin D knock out in the background of DKO significantly antagonized the increase of leukocyte count, especially the monocyte count, in the aging mice, and partially rescued the anemia. We transplanted bone marrow from 5-month-old TKO, DKO, and wildtype mice to 5-month-old lethally irradiated mice, respectively, to investigate whether the rescue effect of gasdermin D knock out was hematopoietic cell intrinsic. As expected, TKO bone marrow transplanted (BMT) mice had significantly less leukocyte count compared with DKO BMT mice, the anemia was also ameliorated in TKO BMT mice. More importantly, gasdermin D depletion in hematopoietic cells significantly extended the survival of DKO mice and reverted the progression to AML, suggesting a critical role of GSDMD in the pathogenesis of MDS. These findings indicate that gasdermin D plays a pivotal role in inflammation related MDS development and progression. This is further supported by the evidence that gasdermin D is highly upregulated in patients with MDS in our preliminary immunohistochemical studies in the bone marrow from patients with different types of MDS. Therefore, targeting gasdermin D could be a novel therapeutic approach in the management of MDS. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document